RxDoctor Payments Data

Saurabh Sharma, MD

Cardiovascular Disease · Sayre, PANPI 1316177058

Payments from drug & device makers

$146,680in general payments, 2019–2025

Across 86 payments — averaging $1705.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$68K
  • Boehringer Ingelheim International GmbH$23K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$23K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
  • Sanofi US Services Inc.$15K
  • Lexicon Pharmaceuticals, Inc.$318
  • plus $699 from 11 others

What the payments were for

  • Food & beverage$90194%
  • Education$596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$146,680 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,504
Medicare patients
722
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$167,831
EntrestoSacubitril/Valsartan74$78,923
JardianceEmpagliflozin68$74,606
XareltoRivaroxaban34$48,347
Repatha SureclickEvolocumab33$25,942
Dofetilide16$4,494
Metoprolol Succinate216$4,031
Atorvastatin Calcium162$1,973
Ezetimibe111$1,898
Rosuvastatin Calcium79$1,234
Isosorbide Mononitrate ErIsosorbide Mononitrate51$1,121
Losartan Potassium51$1,031
Spironolactone97$710
Lisinopril81$519
Simvastatin20$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$167,831144 claims
NovartisEntresto$67,922$78,92374 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →